Melt Pharmaceuticals Concludes Phase 3 Study for MELT-300
Melt Pharmaceuticals, Inc. is thrilled to share significant progress in their clinical journey with MELT-300, a pioneering non-IV, non-opioid tablet designed for procedural sedation. The company announced the completion of patient dosing in its critical Phase 3 clinical study aimed at evaluating the safety and efficacy of MELT-300 for patients undergoing cataract surgery.
MELT-300 combines established agents—midazolam and ketamine—into one effective tablet. This formulation simplifies the sedation process by delivering a fixed combination of midazolam (3mg) and ketamine (50mg) that rapidly dissolves under the tongue thanks to Catalent’s proprietary delivery technology. This innovative method allows for swift absorption of active ingredients necessary for effective sedation.
Overview of the Phase 3 Study
The pivotal Phase 3 trial for MELT-300 is designed as a randomized, double-blind, three-arm study, juxtaposing MELT-300 against both sublingual midazolam and a placebo, following a 4:1:1 randomization ratio. Conducted across 13 clinical sites, the study enrolled over 525 patients, focusing on obtaining a comprehensive topline readout, which is scheduled to be available before the end of 2024.
FDA's Special Protocol Assessment Agreement
In a notable development, Melt Pharmaceuticals has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the MELT-300 trial. This agreement signifies FDA's approval that the study adequately addresses essential objectives needed for future regulatory submissions. It sets a strong foundation for MELT-300’s marketing application by solidifying critical elements of the study design.
Positive Outcomes from Recent Studies
Further bolstering confidence in MELT-300, the FDA has reviewed results from a recent cardiac safety study and concluded that MELT-300 does not adversely affect heart rhythms. This crucial affirmation enhances the product's safety profile, paving the way for its potential approval.
Phase 2 Results Reinforce Promise of MELT-300
Melt Pharmaceuticals previously showcased promising data from the Phase 2 trial of MELT-300, which clearly indicated that MELT-300 significantly outperformed individual sedation methods. Each comparison arm, including both sublingual placebo and standalone sedatives, displayed statistically inferior results when placed against MELT-300.
Comments from the Leadership
Dr. Larry Dillaha, CEO of Melt Pharmaceuticals, expressed enthusiasm over reaching these milestones. He stated that completing the enrollment of the Phase 3 study and securing FDA's SPA are critical steps toward realizing the full potential of MELT-300. He extended gratitude to all the investigators and patients who contributed to this vital study.
Impact on Procedural Sedation Practices
Dr. Dillaha emphasized the importance of MELT-300 in transforming procedural sedation, particularly for the estimated 5 million cataract surgeries performed annually in the U.S. Additional success in MELT-300’s Phase 3 study could broaden its application into other specialties, potentially impacting over 100 million annual procedures in fields such as dermatology and emergency care.
About Melt Pharmaceuticals
Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical innovator committed to developing unique non-IV, non-opioid sedation and analgesia therapies tailored for various medical procedures. The company is focused on navigating the regulatory landscapes, paving the way for its patented product candidates through FDA’s 505(b)(2) pathway when feasible. Melt’s strong intellectual property portfolio includes numerous granted patents across North America, Europe, and other regions.
Previously a subsidiary of Harrow, Inc. (Nasdaq: HROW), Melt Pharmaceuticals has operated independently since its establishment as a managed company in 2019. For more information about Melt, please explore their official website.
Frequently Asked Questions
What is MELT-300 designed for?
MELT-300 is designed to provide needle- and opioid-free sedation for patients undergoing cataract surgery.
How does MELT-300 work?
MELT-300 combines midazolam and ketamine in a single tablet that dissolves sublingually for rapid absorption and effect.
What was the outcome of the Phase 3 study?
The topline results are expected before the end of 2024, and initial indications are promising.
What does the FDA's SPA mean for MELT-300?
The FDA's SPA indicates that the study’s design meets the requirements for a successful marketing application.
How could MELT-300 impact medical procedures overall?
Success with MELT-300 could expand its use beyond cataract surgery, influencing sedation practices in various medical fields.
